Governments must now turn words on paper into practice and take the necessary steps to save more lives of people with TB

Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...

MSF calls on J&J and Cepheid/Danaher to commit to improving access to key TB drug and test by UNHLM 22 September

MSF urges ViiV to withdraw problematic purchasing conditions hindering access to HIV prevention drug CAB-LA

MSF again called on Gavi to broaden catch-up vaccine coverage for children by waiving co-financing requirements of countries with fragile health systems

MSF calls on Johnson & Johnson not to enforce its secondary patents on TB drug bedaquiline

MSF calls on J&J not to enforce secondary patents on TB drug bedaquiline, to improve global access to this lifesaving medicine

MSF signed onto a letter supporting Colombia’s action to possibly issue a compulsory license to improve access to HIV drug dolutegravir

Pro-access recommendations should serve as a blueprint for the EU to ensure equitable global access to medical tools in a future pandemic

Gavi must do more to vaccinate children up to age five, and waive co-financing requirements of countries with fragile health systems or in humanitarian crisis

MSF welcomes WHA resolution on strengthening diagnostic testing in low- and middle-income countries

MSF warned that access to point-of-care CD4 tests for HIV are under threat because Abbott and Becton Dickinson have decided to stop production

Gilead hikes price while liposomal amphotericin B (L-AmB) for treatment of HIV-related cryptococcal meningitis remains unavailable and unaffordable in countries where it’s most needed

MSF appreciates EC pharma legislation proposal to improve transparency by industry and the granting of compulsory licenses on medicines in the EU.

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many

For World Immunization Week 2023, MSF calls on Gavi to expand its policy to catch up young children on missed vaccinations.

With affordable generics likely years away, ViiV must make information public on supply of long-acting cabotegravir and global distribution plan to ensure access for people in high HIV burden low- and middle-income countries

2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.

MSF called on governments and donors to speed up access to diagnostic tests, and shorter, safer and more effective treatments, for DR-TB.

MSF response to negotiations on an India-EU free trade agreement (FTA) regarding harmful intellectual property (IP) provisions